

submitted Claim 1:

E)
D/

1. A polypeptide capable of specifically activating cytotoxic T lymphocytes *in vivo*, wherein said cytotoxic T lymphocytes (CTLs) specifically target malignant cells that express a Her-2/Neu protein, wherein the polypeptide has the amino acid residue sequence of SEQ ID NO:10.

Attached hereto is Appendix A which is the marked-up version of Claim 1.

REMARKS

Claim 1 has been amended to define the invention with more clarity and particularity. Support for the amendment to Claim 1 can be found throughout the specification and, in particular, in the claims as originally filed. No new matter has been added to the specification as a result of these amendments. Claim 1 remains before the Examiner. Applicant hereby respectfully requests re-examination and reconsideration of that claim in its presently amended form.

Specification

Applicants respectfully request that submission of a substitute specification be held in abeyance until claims are allowed.